Comparative Pharmacology
Head-to-head clinical analysis: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE versus LEVATOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE versus LEVATOL.
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE vs LEVATOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dorzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary processes. Timolol is a non-selective beta-adrenergic receptor antagonist that reduces aqueous humor production by blocking beta-2 adrenergic receptors in the ciliary epithelium.
Labetalol is a nonselective beta-adrenergic antagonist with additional alpha1-adrenergic blocking activity. It competitively blocks beta1 and beta2 receptors and alpha1 receptors, leading to decreased heart rate, myocardial contractility, and systemic vascular resistance.
One drop of the fixed combination (dorzolamide 22.26 mg/mL, timolol 6.83 mg/mL) in the affected eye(s) every 12 hours.
50 mg orally once daily, increasing to 100 mg once daily after 2 weeks if tolerated; maximum 200 mg once daily.
None Documented
None Documented
Dorzolamide: ~4 months but accumulates in RBCs; terminal half-life ~4-5 months due to binding to carbonic anhydrase. Timolol: ~4-6 hours.
Terminal elimination half-life is 6-8 hours; prolonged to 10-16 hours in severe renal impairment (CrCl <30 mL/min).
Dorzolamide: primarily renal (approx. 80% unchanged), with minor biliary/fecal elimination. Timolol: renal (15-20% unchanged) and extensive hepatic metabolism with fecal excretion.
Renal excretion accounts for 55-60% as unchanged drug; biliary/fecal elimination accounts for 40-45% as metabolites and unchanged drug.
Category A/B
Category C
Beta-Blocker
Beta-Blocker